CL2004000861A1 - Compuesto biciclico derivado de pirazol [4,3-d] pirimidin-7-ona o de pirazol [4,3-c] piridin-7-ona de formula definida, como ligando del receptor cannabinoide que actua como antagonista del receptor cb1; composicion farmaceutica que comprende al comp - Google Patents

Compuesto biciclico derivado de pirazol [4,3-d] pirimidin-7-ona o de pirazol [4,3-c] piridin-7-ona de formula definida, como ligando del receptor cannabinoide que actua como antagonista del receptor cb1; composicion farmaceutica que comprende al comp

Info

Publication number
CL2004000861A1
CL2004000861A1 CL200400861A CL2004000861A CL2004000861A1 CL 2004000861 A1 CL2004000861 A1 CL 2004000861A1 CL 200400861 A CL200400861 A CL 200400861A CL 2004000861 A CL2004000861 A CL 2004000861A CL 2004000861 A1 CL2004000861 A1 CL 2004000861A1
Authority
CL
Chile
Prior art keywords
receiver
pirazol
ona
cannabinoid
pirimidin
Prior art date
Application number
CL200400861A
Other languages
English (en)
Inventor
Albert Carpino David An Philip
Original Assignee
Pfizer Products Inc Sa Organiz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc Sa Organiz filed Critical Pfizer Products Inc Sa Organiz
Publication of CL2004000861A1 publication Critical patent/CL2004000861A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

COMPUESTOS DE FORMULA (I) QUE ACTUAN COMO LIGANDOS DE RECEPTOR CANNABINOIDE Y SUS USOS EN EL TRATAMIENTO DE ENFERMEDADES LIGADAS A LA MEDIACION DE LOS RECEPTORES CANNABINOIDES EN ANIMALES.
CL200400861A 2003-04-23 2004-04-22 Compuesto biciclico derivado de pirazol [4,3-d] pirimidin-7-ona o de pirazol [4,3-c] piridin-7-ona de formula definida, como ligando del receptor cannabinoide que actua como antagonista del receptor cb1; composicion farmaceutica que comprende al comp CL2004000861A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46491603P 2003-04-23 2003-04-23

Publications (1)

Publication Number Publication Date
CL2004000861A1 true CL2004000861A1 (es) 2005-03-18

Family

ID=33310978

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400861A CL2004000861A1 (es) 2003-04-23 2004-04-22 Compuesto biciclico derivado de pirazol [4,3-d] pirimidin-7-ona o de pirazol [4,3-c] piridin-7-ona de formula definida, como ligando del receptor cannabinoide que actua como antagonista del receptor cb1; composicion farmaceutica que comprende al comp

Country Status (15)

Country Link
US (2) US7141669B2 (es)
EP (1) EP1622902A1 (es)
JP (1) JP2006524222A (es)
AR (1) AR044036A1 (es)
BR (1) BRPI0409689A (es)
CA (1) CA2523205A1 (es)
CL (1) CL2004000861A1 (es)
GT (1) GT200400081A (es)
MX (1) MXPA05011362A (es)
NL (1) NL1026029C2 (es)
PA (1) PA8600501A1 (es)
PE (1) PE20050418A1 (es)
TW (1) TW200424208A (es)
UY (1) UY28278A1 (es)
WO (1) WO2004094417A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375349T1 (de) * 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
US7094572B2 (en) * 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
EP1622876A1 (en) * 2003-05-07 2006-02-08 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) * 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20050026983A1 (en) * 2003-07-30 2005-02-03 Pfizer Inc Imidazole compounds and uses thereof
CN1875021A (zh) * 2003-11-04 2006-12-06 默克公司 取代的萘啶酮衍生物
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
AR051596A1 (es) * 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
JP2008542255A (ja) * 2005-05-27 2008-11-27 ファイザー・プロダクツ・インク 肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
KR101071438B1 (ko) 2005-10-21 2011-10-10 미쓰비시 타나베 파마 코퍼레이션 카나비노이드 수용체 길항제로서의피라졸로[1,5-ａ]피리미딘 화합물
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US20080027087A1 (en) * 2006-02-21 2008-01-31 Ampla Pharmaceuticals, Inc. CB1 antagonists and inverse agonists
ES2402581T3 (es) 2006-02-23 2013-05-06 Pfizer Limited Piperidinoilpirrolidinas como agonistas del receptor de melanocortina tipo 4
CN101454327A (zh) * 2006-03-30 2009-06-10 Irm责任有限公司 作为大麻素1活性抑制剂的吡咯并嘧啶类化合物
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
CA2669311C (en) 2006-11-13 2011-09-20 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
PE20090142A1 (es) * 2007-04-11 2009-02-19 Merck & Co Inc Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1
US8598195B2 (en) * 2008-04-30 2013-12-03 Fredrik Almqvist Peptidomimetic compounds
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
AU2009278838B2 (en) 2008-08-06 2013-07-25 Pfizer Limited Diazepine and diazocane compounds as MC4 agonists
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
CN104611421B (zh) 2008-08-12 2018-08-07 金帆德尔制药股份有限公司 鉴定疾病风险因子的方法
WO2010079241A1 (es) * 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
MX339844B (es) 2011-01-10 2016-06-13 Takeda Pharmaceuticals Co Metodos y productos de farmaco para tratar enfermedad de alzheimer.
EP2674423A4 (en) 2011-02-09 2014-07-30 Nissan Chemical Ind Ltd PYRAZONE DERIVATIVE AND PESTICIDES
US9067943B2 (en) 2011-11-25 2015-06-30 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574493A (en) * 1897-01-05 Charles potter
US4509367A (en) * 1983-05-09 1985-04-09 Lockheed Corporation Tachometer generator indexing device
GB8613591D0 (en) 1986-06-04 1986-07-09 Roussel Lab Ltd Chemical compounds
US5078780A (en) 1986-10-22 1992-01-07 Ciba-Geigy Corporation 1,5-diphenylpyrazole-3-carboxylic acid derivatives for the protection of cultivated plants
GB8905299D0 (en) * 1988-04-09 2013-10-16 Diehl Gmbh & Co A protective arrangement against projectiles
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH0551518A (ja) 1991-08-27 1993-03-02 Dainippon Ink & Chem Inc 硬化性樹脂組成物
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2714057B1 (fr) 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2742148B1 (fr) 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
US5744941A (en) * 1996-05-14 1998-04-28 Bartol; Luis E. Single-wire-connected high-sensitivity dual-mode a.c./d.c. turn-on/turn-off stage for an electronic voltage regulator
EP0971588B1 (en) 1997-01-21 2004-03-17 Smithkline Beecham Corporation Novel cannabinoid receptor modulators
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2761266B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
CA2288097A1 (en) 1998-02-23 1999-08-26 David A. Fussey Parts gripper
CA2342830C (en) 1998-09-04 2008-11-25 Ortho-Mcneil Pharmaceutical, Inc. 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction
IL141769A0 (en) 1998-09-11 2002-03-10 Aventis Pharma Sa Azetidine derivatives, preparation and medicines containing them
FR2783246B1 (fr) 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
MXPA02005100A (es) 1999-10-18 2003-09-25 Alexipharma Inc Derivados de pirazol antagonistas de receptor de canabinoide.
AU1095101A (en) 1999-10-18 2001-04-30 University Of Connecticut, The Cannabimimetic indole derivatives
FR2800372B1 (fr) 1999-11-03 2001-12-07 Sanofi Synthelabo Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
FR2800375B1 (fr) 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
AU2001234958A1 (en) 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US6566356B2 (en) 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6355631B1 (en) 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
US6479479B2 (en) 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
RU2245878C2 (ru) 2000-03-23 2005-02-10 Солвей Фармасьютикалс Б.В. Производные 4,5-дигидро-1н-пиразола, обладающие cb1-антагонистической активностью
FR2809621B1 (fr) 2000-05-12 2002-09-06 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques
US20020019421A1 (en) 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
US20020091114A1 (en) 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
WO2002053565A1 (fr) 2000-12-28 2002-07-11 Ono Pharmaceutical Co., Ltd. Composes de derives tricycliques et heterocycliques et medicaments renfermant ces composes comme principe actif
ES2241994T3 (es) 2001-03-16 2005-11-01 Pfizer Inc. Compuestos pirazolo(4,3-d)pirimidinona como inhibidores de gmpc.
HUP0303148A3 (en) 2001-03-22 2009-08-28 Solvay Pharm Bv 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing the compounds and processes for their preparation
ITMI20011483A1 (it) 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
WO2003007887A2 (en) 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
FR2829027A1 (fr) 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
JP2005507875A (ja) 2001-08-31 2005-03-24 ユニバーシティ オブ コネチカット カンナビノイド受容体に作用する新規なピラゾール類似体
NZ528280A (en) 2001-09-21 2005-11-25 Solvay Pharmaceuticals B 4,5-dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
MXPA04002583A (es) 2001-09-21 2004-06-18 Solvay Pharm Bv Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1).
US6509367B1 (en) 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
JP2005532982A (ja) 2001-09-24 2005-11-04 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのピロール誘導体の製造及び使用
CA2461142A1 (en) 2001-09-24 2003-04-03 Bayer Pharmaceuticals Corporation Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
UY27450A1 (es) 2001-09-24 2003-04-30 Bayer Corp Preparación y uso de derivados de imidazol para el tratamiento de la obesidad
US20030068339A1 (en) 2001-10-02 2003-04-10 Phoenix Scientific, Inc. Veterinary florfenicol formulation that is syringeable under cold weather conditions
US7244744B2 (en) 2001-11-01 2007-07-17 Icagen, Inc. Piperidines
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
DE60228611D1 (de) * 2001-11-29 2008-10-09 3M Innovative Properties Co Pharmazeutische formulierung umfassend ein die immunantwort modifizierendes mittel
SE0104332D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104330D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
US20030139386A1 (en) 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
US20050171161A1 (en) 2002-03-06 2005-08-04 Fong Tung M. Method of treatment or prevention of obesity
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
AR038966A1 (es) 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
JP2005528366A (ja) 2002-03-26 2005-09-22 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体モジュレータとしてのスピロ環式アミド
ES2192494B1 (es) 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
GB0207249D0 (en) 2002-03-27 2002-05-08 Glaxo Group Ltd Novel compounds
FR2837706A1 (fr) 2002-03-28 2003-10-03 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles
US7271266B2 (en) 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
CA2480856A1 (en) 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
FR2838439B1 (fr) 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
US7667053B2 (en) 2002-04-12 2010-02-23 Merck & Co., Inc. Bicyclic amides
AU2003226938A1 (en) 2002-04-12 2003-10-27 Lars Broen A bag for a medical item such as an x-ray cassette
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
JP2005529919A (ja) 2002-05-10 2005-10-06 スミスクライン ビーチャム コーポレーション 治療用化合物
EP1545370B1 (en) 2002-08-02 2008-12-10 Warsaw Orthopedic, Inc. Systems and techniques for illuminating a surgical space
MXPA05004115A (es) 2002-10-18 2005-06-22 Pfizer Prod Inc Ligandos del receptor cannabionoide y usos de los mismos.
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof

Also Published As

Publication number Publication date
US20040214838A1 (en) 2004-10-28
EP1622902A1 (en) 2006-02-08
PE20050418A1 (es) 2005-06-18
GT200400081A (es) 2005-02-16
US7354929B2 (en) 2008-04-08
PA8600501A1 (es) 2004-12-16
UY28278A1 (es) 2004-11-30
US7141669B2 (en) 2006-11-28
JP2006524222A (ja) 2006-10-26
TW200424208A (en) 2004-11-16
CA2523205A1 (en) 2004-11-04
NL1026029C2 (nl) 2005-07-05
NL1026029A1 (nl) 2004-10-27
MXPA05011362A (es) 2005-11-28
AR044036A1 (es) 2005-08-24
WO2004094417A1 (en) 2004-11-04
US20070105856A1 (en) 2007-05-10
BRPI0409689A (pt) 2006-04-18

Similar Documents

Publication Publication Date Title
CL2004000861A1 (es) Compuesto biciclico derivado de pirazol [4,3-d] pirimidin-7-ona o de pirazol [4,3-c] piridin-7-ona de formula definida, como ligando del receptor cannabinoide que actua como antagonista del receptor cb1; composicion farmaceutica que comprende al comp
CL2004000860A1 (es) Compuesto biciclico de pirazol o imidazol de formula definida, como ligando del receptor cannabinoide que actua como antagonista del receptor cb1; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de un medicam
CR7932A (es) Pirazolo (1,5-a) (1,3,5) derivados de triazina como ligandos de receptor de cannabinoides
ECSP066549A (es) Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos
ECSP056117A (es) Ligandos de receptores de cannabinoides y sus usos
CR7812A (es) Compuestos de purina y usos de los mismos como ligandos de receptor de cannabinoides
DOP2002000412A (es) Ligandos del receptor de 5-ht y sus usos
CR8759A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores quimioquinas
UY28275A1 (es) Ligandos de receptores de cannabinoides y sus usos
MXPA05007938A (es) Ligandos de receptores de cannabinoides y usos de los mismos.
ECSP045139A (es) DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTICA DE MGluR5
CR8775A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
UY27026A1 (es) Derivados benzodiacepínicos como moduladores de los receptores gaba a
BRPI0412843A (pt) lactamas substituìdas e uso das mesmas como agentes anticáncer
UY28599A1 (es) Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos
DOP2004000885A (es) Ligandos de receptor cannabinoide y usos de los mismo
CR7169A (es) Ligandos del receptor de 5-ht y sus usos
DOP2001000251A (es) Antagonistas de receptores de taquiquinina zwitterionica.
DOP2004000884A (es) Ligandos de receptores de cannabinoides y sus usos
CR8052A (es) Ligandos del receptor cannabinoide y usos de los mismos
DOP2004000810A (es) Compuestos de pirazolotriazina y usos de los mismos
UY26579A1 (es) Moduladores de receptores canabinoides, sus procesos de preparación y uso de los moduladores de receptores canabinoides para el tratamiento de enfermedades respiratorias y no respiratorias
SV2002000513A (es) Ligandos para receptores de melanocortina ref.pc10861abtc/bb